FGFR2 and breast carcinoma: The confirmed ORR was 41.7% (43/103) and the disease control rate was 82.5%15; based on this data, the FDA granted accelerated approval to futibatinib for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic CCA harboring FGFR2 gene fusions or other rearrangements5. In this study, we aimed to elucidate the efficacy of futibatinib in breast cancer and identify the molecular features associated with its antitumor activity.